XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold

The latest update is out from XORTX Therapeutics Inc ( (TSE:XRTX) ).

XORTX Therapeutics reported in a May 8, 2026 filing that it currently estimates stockholders’ equity at approximately $4.1 million, above the Nasdaq Capital Market’s minimum equity requirement for continued listing. The estimate reflects the company’s financial position as of March 31, 2026 and incorporates the April 13, 2026 closing of its acquisition of Vectus Biosystems’ VB4-P5 asset.

The company emphasized that the equity figures are preliminary, unaudited and subject to change once its March 31, 2026 financial statements are finalized. XORTX cautioned investors that actual results for the first and second quarters of 2026 may differ materially from these estimates, underscoring ongoing uncertainty even as it seeks to demonstrate continued compliance with Nasdaq listing standards.

Spark’s Take on XRTX Stock

According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.

The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn with equity erosion), partially offset by improving technical momentum (price above key short/intermediate moving averages and positive MACD). Valuation provides limited support due to negative earnings and no dividend.

To see Spark’s full report on XRTX stock, click here.

More about XORTX Therapeutics Inc

XORTX Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing therapies for kidney diseases and related indications. The company is advancing product candidates through preclinical studies and clinical trials, with an emphasis on expanding applications in kidney disease and strengthening its position on North American capital markets.

Average Trading Volume: 2,454

Technical Sentiment Signal: Sell

Current Market Cap: C$5.08M

See more data about XRTX stock on TipRanks’ Stock Analysis page.